No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.4800
- +0.0400+2.78%
Close Dec 20 16:00 ET
- 1.4400
- -0.0400-2.70%
Post 20:01 ET
9.02MMarket Cap-0.57P/E (TTM)
1.5000High1.4200Low213.57KVolume1.4200Open1.4400Pre Close310.91KTurnover3.94%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.64P/B8.02MFloat Cap1.290052wk Low--Dividend TTM5.42MShs Float1419.0000Historical High--Div YieldTTM5.56%Amplitude1.2900Historical Low1.4550Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Can-Fite Biopharma Has Received A Notice Of Allowance For A US Patent Titled "AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT (FOR THE TREATMENT OF OBESITY)"
Bears Are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital
Can-Fite Biopharma Price Target Maintained With a $10.00/Share by D. Boral Capital
Can-Fite BioPharma's Namodenoson Shows Promising Cancer Results
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug
Heat List
US
Overall
Symbol
Price
% Chg
No Data